Tramadol Hydrochloride
Product Images NDC 45865-876

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tramadol Hydrochloride (NDC 45865-876). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (876)

Label for TRAMADOL HCL ER 100MG tablets by Medsource Pharmaceuticals. The label shows the product as extended-release tablets containing 100 mg of tramadol hydrochloride. The package contains 30 tablets, with a description of the tablet as white and round. The label also includes manufacturer information: Sun Pharma Ind. Ltd., Gujarat, India, and warnings about dizziness, drowsiness, and alcohol avoidance.*

FDA Label Image

Tramadol-figure1 (Tramadol Figure1)

A line graph comparing tramadol plasma concentration (ng/mL) over 24 hours between Tramadol Hydrochloride Extended-Release Tablets 200 mg once daily and Tramadol Immediate-Release Tablets 50 mg every 6 hours. The x-axis represents time in hours (0 to 24), and the y-axis shows tramadol concentration.*

FDA Label Image

Tramadol-figure2 (Tramadol Figure2)

A line graph comparing M1 metabolite concentration (ng/mL) over 24 hours between Tramadol Hydrochloride Extended-Release Tablets 200 mg taken once daily and Tramadol IR Tablets 50 mg taken every 6 hours. The graph shows concentration over time with the extended-release formulation maintaining more stable levels than the immediate-release tablets.*

FDA Label Image

Tramadol-figure3 (Tramadol Figure3)

A line graph titled 'Tramadol Hydrochloride Extended-Release Tablets Study 023 WOMAC Pain Responder Analysis' showing the percent of patients achieving various response thresholds. The x-axis represents response threshold as percent improvement from baseline (0 to 100%), and the y-axis shows percent of patients achieving response (0 to 60%). Multiple lines compare different tablet doses (100mg, 200mg, 300mg, 400mg) and placebo.*

FDA Label Image

Tramadol-figure4 (Tramadol Figure4)

A line graph titled 'Tramadol Hydrochloride Extended-Release Tablets Study 015 Arthritis Pain Intensity VAS Responder Analysis.' It shows the percent of patients achieving response versus response threshold (percent improvement from baseline) comparing Tramadol Hydrochloride Extended-Release Tablets to placebo. The graph indicates a higher percentage of response with Tramadol Hydrochloride tablets across varying improvement thresholds.*

FDA Label Image

Tramadol-structure (Tramadol Structure)

Chemical structure of Tramadol Hydrochloride showing its molecular components, including a cyclohexane ring, methoxyphenyl group, hydroxyl group, and dimethylaminomethyl side chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.